Clinical trials: Tourette's Syndrome
Tourette Syndrome
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome…
- Trial name
- NCT00681863
- Testing
- pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID
- Where
- 14 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Tourette Syndrome
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS.
- Trial name
- ALLEVIA2 (NCT06315751)
- Testing
- Gemlapodect
- Where
- 46 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Noema Pharma AG
Tourette Syndrome
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance…
- Trial name
- ARTISTS (NCT03567291)
- Testing
- TEV-50717
- Where
- 76 sites in United States, Argentina and 13 more
- Volunteers
- 228 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tourette Syndrome in Children, Tourette Syndrome in Adolescence
A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome
A 12-week clinical study to evaluate the safety and efficacy of T92 in pediatric patients with Tourette Syndrome.
- Trial name
- NCT05188274
- Testing
- T92
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Tasly Pharmaceuticals, Inc.